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Abstract
Background: Milk phospholipids (PLs) reduce liver lipid levels when given as a dietary supplement to mice fed a
high-fat diet. We have speculated that this might be due to reduced intestinal cholesterol uptake.
Methods: Mice were given a high-fat diet for 3 or 5 weeks that had no added PL or that were supplemented with
1.2% by wt PL from cow’s milk. Two milk PL preparations were investigated: a) a PL-rich dairy milk extract
(PLRDME), and b) a commercially-available milk PL concentrate (PC-700). Intestinal cholesterol uptake was assessed
by measuring fecal and hepatic radioactivity after intragastric administration of [
14C]cholesterol and [
3H]sitostanol.
Fecal and hepatic lipids were measured enzymatically and by ESI-MS/MS.
Results: Both PL preparations led to significant decreases in total liver cholesterol and triglyceride (-20% to -60%,
P < 0.05). Hepatic accumulation of intragastrically-administered [
14C]cholesterol was significantly less (-30% to -60%,
P < 0.05) and fecal excretion of [
14C]cholesterol and unlabeled cholesterol was significantly higher in PL-
supplemented mice (+15% to +30%, P < 0.05). Liver cholesterol and triglyceride levels were positively correlated
with hepatic accumulation of intragastrically-administered [
14C]cholesterol (P < 0.001) and negatively correlated
with fecal excretion of [
14C]cholesterol (P < 0.05). Increased PL and ceramide levels in the diet of mice
supplemented with milk PL were associated with significantly higher levels of fecal PL and ceramide excretion, but
reduced levels of hepatic PL and ceramide, specifically, phosphatidylcholine (-21%, P < 0.05) and
monohexosylceramide (-33%, P < 0.01).
Conclusion: These results indicate that milk PL extracts reduce hepatic accumulation of intestinal cholesterol and
increase fecal cholesterol excretion when given to mice fed a high-fat diet.
Background
Dietary phospholipids (PLs) have been shown to reduce
plasma and liver lipid levels in experimental animals [1],
suggesting that they might be of therapeutic value in
patients with hyperlipidemia and/or fatty liver disease.
Our laboratory has therefore been investigating the
lipid-lowering properties of PL from different sources
[2-4], and we have shown that a PL-rich dairy
milk extract (PLRDME), containing predominantly
phosphatidylcholine (PC), sphingomyelin (SM) and
phosphatidylethanolamine (PE), significantly lowers
plasma and liver lipid levels in mice fed a high-fat diet.
Addition of 2.5% by weight (wt) of milk PL extract to a
diet containing 21% butterfat and 0.15% cholesterol
resulted in lower levels of serum cholesterol (-23%), and
significantly reduced levels of liver triglyceride (-44%)
and liver cholesterol (-48%) [2].
Unlike PL from vegetable sources, milk PLs contain a
low level of polyunsaturated fatty acids, i.e., they have a
polyunsaturated:monounsaturated:saturated fatty acid
ratio of 10:30:60. The ability of dietary PL to lower
plasma and liver lipid levels in mice fed a high-fat diet
is therefore unlikely to be due to their polyunsaturated
* Correspondence: cohnj@hri.org.au
1Nutrition and Metabolism Group, Heart Research Institute, Sydney, Australia
Full list of author information is available at the end of the article
Kamili et al. Nutrition & Metabolism 2010, 7:90
http://www.nutritionandmetabolism.com/content/7/1/90
© 2010 Kamili et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.fatty acid content. This is supported by recent work
from our laboratory showing that hydrogenated egg and
soy PC, containing only saturated fatty acids (i.e., C16:0
and C18:0), lower liver lipids to a greater extent than
non-hydrogenated PC preparations, containing 20% and
70% polyunsaturated fatty acids respectively (i.e., C18:2
and C18:3) [4]. A possible mechanism is that: a) lipid-
lowering is dependent on the ability of dietary PL to
reduce intestinal cholesterol absorption and b) that PLs
containing saturated fatty acids are more efficacious
inhibitors of intestinal cholesterol absorption than PLs
containing unsaturated fatty acids [5]. The ability of spe-
cific types of PL to affect cholesterol absorption has
been previously documented, and egg PC containing a
higher proportion of saturated fatty acids than soy PC
has been shown to be more efficacious in reducing the
lymphatic absorption of cholesterol in experimental rats
[6]. Milk SM, containing longer and more saturated
f a t t ya c i d s ,h a si nt u r nb e e ns h o w nt ob eam o r ee f f e c -
tive inhibitor than egg SM [7]. In vitro, uptake and
esterification of cholesterol by human intestinal Caco-2
cells is reduced to a greater extent by milk SM or by
dipalmitoyl PC (containing saturated fatty acids) than by
egg yolk PC, and in mice, milk SM or dipalmitoyl PC,
but not egg PC, has been shown to cause a dose-depen-
dent decrease in cholesterol absorption [8].
The aforementioned results have led us to speculate
that PL extracts from milk (containing several species of
PL with predominantly saturated fatty acids) might be
of therapeutic value in humans. The ability of milk PL
extracts to affect intestinal fat metabolism in experimen-
tal animals fed an obesogenic/atherogenic diet has not
been investigated however, and the extent to which
their intestinal effects are related to hepatic lipid-lower-
ing has not been evaluated. The aim of the present
study therefore was to determine: a) whether dietary
milk PL extracts containing different PL species were
able to inhibit intestinal cholesterol absorption in mice
fed a high-fat diet, and b) the extent to which these
milk PL effects in the intestine were related to their
potent ability to reduce cholesterol and triglyceride
levels in the liver.
Methods
Animals and diets
Four to five-week-old male C57BL/6 mice were obtained
from Monash University, Melbourne. They were housed
in standard cages (5 mice per cage) at a constant tem-
perature of 21°C with a 12-h light/dark cycle. They were
allowed ad libitum access to diet and water. After 1
week of acclimatization on normal chow diet, mice (n =
10 per group) were given a high-fat semi-purified diet
(HF) with or without added PL. Diets were given for 3,
5 or 8 weeks, depending on the protocol of the
experiment. The HF diet contained 21% wt/wt butterfat
and 0.15% wt/wt cholesterol. Its composition was as fol-
lows (g/kg): casein, 195; DL-methionine, 3; sucrose
341.8; wheat starch, 154; cellulose, 50; clarified butter,
210; calcium carbonate, 17.1; sodium chloride, 2.6;
potassium citrate, 2.6; potassium dihydrogen phosphate,
6.9; potassium sulphate, 1.6; AIN93G trace minerals, 1.4;
choline chloride (65%), 2.5; vitamins, 10; cholesterol, 1.5.
PL-supplemented diets (HFPL) were prepared by adding
either 2.5% (wt/wt) phospholipid-rich dairy milk extract
(PLRDME) or 2% (wt/wt) commercially-prepared phos-
pholipid concentrate 700 (PC-700) to the HF diet.
These additions resulted in diets containing equivalent
amounts of milk PL (i.e., 1.2% wt/wt). As described pre-
viously [2), 57% by wt of PLRDME was fat and 48% of
the extract was PL. The major PL components were PE
(29%), PC (26%) and SM (22%), with smaller amounts of
phosphatidylserine (PS) and phosphatidylinositol (PI).
The remaining PL consisted of lysophospholipids. The
main fatty acids present were palmitic (16:0), stearic
(18:0) and oleic (18:1) acids (i.e., 29%, 10% and 26%,
respectively). The polyunsaturated:monounsaturated:
saturated fatty acid ratio was 10:30:60. About one-third
of the extract by wt was composed of milk protein, prin-
cipally casein. The PLRDME was provided by MG
Nutritionals (Melbourne, Australia), and was stored at
4°C in vacuum sealed bags in the dark. The PC-700 was
provided by Fonterra (Palmerston North, New Zealand).
Total fat content of the PC-700 was 85% and 7% was
lactose. Sixty percent by wt of the extract was PL. This
was comprised of 32% PC, 28% PE and 28% SM. Princi-
pal fatty acids were: oleic acid (18:1) 31%, palmitic acid
(16:0) 21% and stearic acid (18:0) 11%. Food consump-
tion was recorded three times per week and body weight
was monitored weekly. Experiments were conducted in
conformity with the Public Health Service (PHS) Policy
on Humane Care and Use of Laboratory Animals and
were approved by the Animal Welfare Committee of the
Sydney South West Area Health Service.
Assessment of intestinal cholesterol absorption
Fecal dual-isotope ratio methodology was used to assess
intestinal cholesterol absorption. This methodology is
based on the intragastric administration of radiolabeled
cholesterol and a radiolabeled phytosterol. It is assumed
that the phytosterol is not absorbed in the intestine and
is completely excreted in the feces, thus acting as a mar-
ker of sterol passage through the intestinal tract. The
ratio of the two sterols in the feces is thus used to
calculate percentage cholesterol absorption [9]. Radiola-
beled sterols were administered in two separate experi-
ments. In the first experiment, groups of mice (n = 10)
were given HF and HFPL diets containing PLRDME for
two different time periods (i.e., a total of 40 mice were
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protocol was followed except that the PL-supplemented
diet contained PC-700 (designated HFPC-700). After
2 or 4 weeks on diet, mice were given a dose of 200 μl
olive oil containing 1 μCi [
14C]cholesterol and 1 μCi
[
3H]sitostanol by intragastric gavage under light methox-
yflurane anaesthesia. Mice were then transferred into
individual cages with perforated-metal floors. Feces were
collected daily for 4 days and stored at -80°C until ana-
lysis. Mice were given access to their respective diets
during this collection period. At the end of fecal collec-
t i o n ,m i c ew e r ea n a e s t h e t i z ed with methoxyflurane and
exsanguinated by heart puncture. The total duration of
diet feeding was therefore 2 weeks and 4 days, or
4 weeks and 4 days respectively, which for the sake of
simplicity were designated as 3- or 5-week dietary
periods.
Blood was allowed to clot and serum was separated by
centrifugation (1500× g, 10 min). Sera were aliquoted
and stored frozen (-80°C) until analysis. Livers were
immediately excised, weighed and divided into small
pieces (100-150 mg) for storage at -80°C (for lipid and
radioactivity analysis). Fecal samples collected for each
animal over 4 days were combined and were dried in an
oven at 60°C for 24 h. Dried feces were ground to a fine
powder using a mortar and pestle. In order to extract
total lipid, 100 mg aliquots of the powder and triplicate
10 μl aliquots of the original dosing mixture were added
to 1.2 ml of chloroform:methanol (2:1, v/v). Nitrogen-
dried lipid extract was ‘saponified’ i n1m lo f2 N
NaOH : methanol (1:1, v/v) and incubated at 60°C for 1
h. Labelled sterols were then extracted into 2 ml of
diethyl ether. Duplicate 500 μl aliquots of the organic
phase were transferred into scintillation vials and dried.
Scintillation fluid (5 ml) was added and radioactivity
was counted. Total liver and fecal lipids were deter-
mined gravimetrically after extraction with chloroform:
methanol. Individual hepatic and fecal lipids were quan-
titated enzymatically after solubilization in isopropanol.
Triglyceride and total cholesterol concentrations were
measured by using GPO-PAP and CHOD-PAP kits
(Roche Diagnostics), respectively.
Phospholipid and ceramide analysis by ESI-MS/MS
In brief, lipids were extracted from liver homogenate
(12.5 μlo f2m g / m lp r o t e i n ) ,1m gf e c e s ,o r2 5 0μg
food samples. Lipids were extracted with chloroform/
methanol (2:1; 20 volumes) following the addition of
internal standards (100 pmol each of ceramide (Cer)
17:0, glucosylceramide (GC) 16:0 d3 and lactosylcera-
mide (DHC) 16:0 d3 (Matreya Inc., Pleasant Gap,
USA), phosphatidylcholine (PC) 13:0/13:0, phosphatidy-
lethanolamine (PE) 17:0/17:0, phosphatidylserine (PS)
17:0/17:0 and sphingomyelin (SM) 12:0 (Avanti Polar
Lipids, Alabaster, USA), together with 1000 pmol each
of free cholesterol (d7) (Avanti Polar Lipids, Alabaster,
USA) and cholesteryl ester (CE) 18:0 (d6) (CDN Iso-
topes, Pointe-Claire, Quebec, Canada).). Samples were
vortexed, mixed for 10 min on a rotation mixer,
sonicated for 30 minutes and left to stand at room
temperature for a further 20 min. Extracts were then
centrifuged at 13,000× g for 10 minutes, the superna-
tant was transferred to a clean tube and dried under
nitrogen at 40°C. Lipids were redissolved in 50 μlw a t e r
saturated BuOH containing 10 mM NH4COOH then
50 μl MeOH containing 10 mM NH4COOH was
added. Analysis was performed by electrospray ionisa-
tion-tandem mass spectrometry using a PE Sciex API
4000 Q/TRAP mass spectrometer with a turbo-ionspray
source and Analyst 1.5 data system. Prior liquid chro-
matographic separation was performed on a Zorbax
C18, 1.8 μm, 50 × 2.1 mm column at 300 μl/min using
the following gradient conditions; 100% A to 0% A
over 8.0 min followed by 2.5 min at 0% A, a return to
100% A over 0.5 min then 3.0 min at 100% A prior to
the next injection. Solvent A and B consisted of tetra-
hydrofuran:methanol:water in the ratios (30:20:50) and
(75:20:5) respectively, both containing 10 mM
NH4COOH. Quantification of individual lipid species
was performed using scheduled multiple-reaction moni-
toring (MRM) in positive ion mode. Individual lipid
species monitored were the major species (greater than 1%
of total) identified in human plasma. MRM experiments
were based on product ion of m/z 264 [sphingosine-
H2O]
+ for Cer, GC and DHC, m/z 184 [phosphocholine]
+
for SM and PC, m/z 369 [cholesterol-H2O]
+ for choles-
terol and CE and neutral loss (NL) of 141 Da for PE,
185 Da for PS and 277 Da for PI. Each ion pair was
monitored for 10-50 ms with a resolution of 0.7 amu at
half-peak height and averaged from continuous scans
over the elution period. Lipid concentrations were calcu-
lated by relating the peak area of each species to the
peak area of the corresponding internal standard. PI spe-
cies were related to the PE internal standard. Total lipids
of each class were calculated by summing the individual
lipid species.
Statistical analysis
Values in the text and tables are means ± SEM. Prism 4
for Macintosh (version 4.0c, GraphPad Software, Inc.)
was used for statistical analyses. Significant differences
between HF and HFPL groups were assessed by Stu-
dent’s t-test. Pearson correlation coefficients (r) were
determined to assess the relationship between para-
meters. A probability of P < 0.05 was considered to be
statistically significant.
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Metabolic effects of PLRDME supplementation
Metabolic parameters were assessed after 3 or 5 weeks
in mice fed the HF diet alone and in those given the HF
diet supplemented with PLRDME (Table 1). Three mice
had to be excluded because either they did not survive
the gavage or they were not metabolically stable follow-
ing the procedure. Addition of PLRDME to the HF diet
had no significant effect on food intake, weight gain or
fecal excretion. Liver wt tended to be lower in HFPL vs
HF after 3 weeks (11%, P = 0.095). This was less evident
after 5 weeks (5%, P = 0.37). Liver to body wt ratios
were however significantly lower in HFPL vs HF after 3
weeks (12%, P = 0.02) and tended to be lower after 5
weeks (9%, P = 0.06) (Table 1).
Total lipid, cholesterol and triglyceride were signifi-
cantly lower in the livers of HFPL vs HF mice (-25%,
-21% and -35%, respectively) after 3 weeks on diet
(Table 2). The lipid-lowering effect of PLRDME was
more pronounced after 5 weeks of feeding (i.e., -41%,
-39%, and -47%, respectively). When data were com-
b i n e d ,a ss h o w no nt h er i g h to fT a b l e2 ,P L R D M E
supplementation was on average associated with a
one-third reduction in hepatic lipids. Hepatic accumu-
lation of intragastrically-administered [
14C]cholesterol
was also significantly lower in HFPL vs HF mice (-45%
and -34% at 3 and 5 weeks, respectively), which was
associated with an increase in fecal [
14C]cholesterol
excretion. When percentage cholesterol absorption
was calculated however, no significant differences
were observed. At 3 weeks, percentage cholesterol
absorption was 52.7 ± 3.7% and 48.4 ± 4.4%, and at 5
weeks it was 55.8 ± 3.1 and 56.9 ± 2.7% for HF vs
HFPL mice, respectively. This was due to an unex-
pected increase in [
3H]sitostanol in the feces of HFPL
vs HF mice, particularly at 3 weeks. Hepatic accumu-
lation of intragastrically-administered [
3H]sitostanol
was in turn lower in HFPL vs HF mice, although this
was not statistically significa n ta t3w e e k s .I nc o n t r a s t ,
total fecal lipid and cholesterol excretion were
increased in HFPL vs HF animals, particularly at
3 weeks. No significant differences were observed in
fecal triglyceride excretion. Overall, the combined data
(right-hand side of Table 2) showed that PLRDME
supplementation resulted in a significant increase in
the excretion of intragastrically-administered choles-
terol and plant sterol (by 30% and 25%, respectively).
The calculated percentage cholesterol absorption did
not change, though this calculation had limited valid-
ity considering that differences were observed in the
intestinal metabolism of intragastrically-administered
[
3H]sitostanol.
Metabolic effects of PC-700 supplementation
In order to confirm the effect of milk PL on intestinal
cholesterol and plant sterol uptake, a second milk PL
preparation was investigated (i.e., PC-700). This com-
mercially-available milk PL concentrate contained more
total fat (85% vs 57% by wt) and more PL (60% vs 48%
by wt) than PLRDME. Less PC-700 was therefore added
to the HF diet, to ensure that the HFPL diets contained
comparable amounts of milk PL (i.e.,1.2% by wt). The
PC-700 and the PLRDME had a similar PL composition
(comprising primarily PC, PE and SM) and a similar
fatty acid composition (comprising predominantly pal-
mitic, stearic and oleic acids).
Mice were fed the HF diet and the HF diet containing
PC-700 (designated the HFPC-700 group). They were
studied in the same way as in the first experiment.
Metabolic parameters for these animals are given in
Table 3. Two mice had to be excluded from the analysis
since they did not react well to the intragastric gavage.
Addition of PC-700 to the HF diet had no significant
effect on any of the parameters. The tendency of
PLRDME to reduce liver weight was not evident in mice
supplemented with PC-700.
Table 1 Body weight, liver weight, food intake and fecal excretion of mice fed the high-fat diet alone (HF) or the
high-fat diet supplemented with milk phospholipids (HFPL) in the form of phospholipid-rich dairy milk extract
(PLRDME)
3 weeks 5 weeks
HF HFPL HF HFPL
(n = 10) (n = 8) (n = 9) (n = 10)
Initial body wt (g) 17.6 ± 0.5 17.1 ± 0.9 18.0 ± 0.5 17.6 ± 0.8
Final body wt (g) 23.6 ± 0.5 23.8 ± 0.6 27.7 ± 0.6 28.8 ± 0.8
Wt gain (g) 6.0 ± 0.3 6.7 ± 0.6 9.7 ± 0.7 11.3 ± 0.5
Liver wt (g) 1.20 ± 0.04 1.07 ± 0.06 1.35 ± 0.06 1.29 ± 0.04
Liver wt/body wt (g/100 g) 5.07 ± 0.17 4.48 ± 0.15 * 4.90 ± 0.20 4.47 ± 0.09
Food intake (g/mouse/day) 3.5 ± 0.3 3.2 ± 0.1 2.9 ± 0.1 3.1 ± 0.1
Fecal excretion (g/mouse/day) 0.23 ± 0.02 0.26 ± 0.01 0.23 ± 0.01 0.22 ± 0.01
Values represent means ± SEM. Significant difference between HF and HFPL groups by Student’s t-test: * P < 0.05
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lower in the livers of HFPC-700 vs HF mice (-22%, -45%
and -35%, respectively) after 3 weeks on diet, although
this reached statistical significance only for liver choles-
terol (Table 4). As in the first experiment with
PLRDME, the lipid-lowering effect of PC-700 was more
pronounced after 5 weeks of feeding (i.e., -45%, -57%,
and -63%, respectively). Hepatic accumulation of
intragastrically-administered [
14C]cholesterol was also
significantly lower in HFPC-700 vs HF mice (-60% and
-65% at 3 and 5 weeks, respectively). Intestinal absorp-
tion of [
3H]sitostanol was once again evidenced by the
presence of intragastrically-administered [
3H]sitostanol
in the liver. It was lower in HFPC-700 vs HF mice,
reaching statistical significance when 3-and 5-week data
were combined (as shown on the right in Table 4). The
Table 2 Effect of dietary milk phospholipids in the form of phospholipid-rich dairy milk extract (PLRDME) on liver and
fecal lipid parameters in mice given an intragastric gavage of radioactively labelled cholesterol and sitostanol after 3
or 5 weeks on high-fat diet
3 weeks 5 weeks Combined
HF HFPL difference HF HFPL difference HF HFPL difference
(n = 10) (n = 8) (n = 9) (n = 10) (n = 19) (n = 18)
Liver
Total lipid (mg/organ) 118 ± 6 89 ± 10 * -25% 212 ± 19 126 ± 7 *** -41% 162 ± 14 110 ± 7 ** -32%
Cholesterol (μmol/
organ)
33 ± 1 26 ± 3 * -21% 64 ± 8 39 ± 4 ** -39% 48 ± 5 33 ± 3 * -31%
Triglyceride (μmol/
organ)
65 ± 5 42 ± 8 * -35% 168 ± 14 90 ± 10 *** -47% 114 ± 14 70 ± 9 * -38%
[
14C]cholesterol (dpm/
organ)
6819 ±
836
3737 ± 948 * -45% 13560 ±
1737
9021 ± 1043 * -34% 10012 ±
1204
6673 ± 943 * -33%
[
3H]sitostanol (dpm/
organ)
317 ± 31 244 ± 52 -23% 547 ± 41 370 ± 38 ** -32% 426 ± 37 318 ± 34 * -25%
Feces
Total lipid (mg/
mouse/day)
6.4 ± 0.6 10.6 ± 0.7 *** +66% 9.2 ± 1.0 10.2 ± 1.1 +11% 7.8 ± 0.7 10.4 ± 0.7 * +33%
Cholesterol (μmol/
mouse/day)
7.3 ± 0.4 9.1 ± 0.5 * +25% 6.7 ± 0.3 7.4 ± 0.4 +11% 7.0 ± 0.3 8.1 ± 0.4 * +16%
Triglyceride (μmol/
mouse/day)
0.9 ± 0.1 1.0 ± 0.2 +11% 2.6 ± 0.5 2.0 ± 0.4 -24% 1.8 ± 0.3 1.6 ± 0.3 -11%
[
14C]cholesterol (dpm/
mouse/day)
9195 ±
1187
13454 ± 996 * +46% 8889 ±
795
10245 ± 864 +15% 9050 ±
711
11765 ± 740 * +30%
[
3H]sitostanol (dpm/
mouse/day)
12376 ±
1275
17110 ± 712 ** +38% 16076 ±
570
18134 ± 777 +13% 14129 ±
828
17679 ± 535 ** +25%
Results represent means ± SEM. Mice given the high-fat diet alone were designated HF. Mice given the high-fat diet supplemented with 2.5% by wt PLRDME
were designated HFPL. Data are provided for animals fed for 3 or 5 weeks. Combined data are shown on the right. Percentage difference between groups is
given in italics. Significant difference between HF and HFPL by Student’s t-test: * P < 0.05, ** P < 0.01, *** P < 0.001.
Table 3 Body weight, liver weight, food intake, and fecal excretion of mice fed the high-fat diet alone (HF) or the
high-fat diet supplemented with milk phospholipids (HFPC-700) in the form of commercially-prepared PC-700
3 weeks 5 weeks
HF HFPC-700 HF HFPC-700
(n = 10) (n = 9) (n = 9) (n = 10)
Initial body wt (g) 17.0 ± 0.8 17.1 ± 0.6 16.6 ± 0.6 17.0 ± 0.4
Final body wt (g) 25.3 ± 0.5 24.6 ± 0.6 28.7 ± 0.7 29.0 ± 0.9
Wt gain (g) 8.3 ± 0.8 7.5 ± 0.7 12.1 ± 0.9 12.0 ± 0.9
Liver wt (g) 1.14 ± 0.05 1.12 ± 0.04 1.21 ± 0.08 1.12 ± 0.06
Liver wt/body wt
(g/100 g)
4.54 ± 0.25 4.58 ± 0.19 4.24 ± 0.30 3.90 ± 0.24
Food intake (g/mouse/day) 3.1 ± 0.1 3.1 ± 0.1 3.2 ± 0.1 3.2 ± 0.1
Fecal mass (g/mouse/day) 0.31 ± 0.01 0.34 ± 0.01 0.35 ± 0.02 0.35 ± 0.02
Values represent means ± SEM. No significant differences were observed between HF and HFPC-700 groups
Kamili et al. Nutrition & Metabolism 2010, 7:90
http://www.nutritionandmetabolism.com/content/7/1/90
Page 5 of 12combined data demonstrated that PC-700 supplementa-
tion was associated with an approximate 30% to 65%
reduction in hepatic lipid parameters, which was similar
in magnitude to that obtained with the PLRDME. It
should be noted however that experiments with
PLRDME and PC-700 were not conducted simulta-
neously and it was therefore difficult to directly compare
the efficacy of the two PL preparations.
Total fecal lipid and cholesterol excretion were in con-
trast increased in HFPC-700 vs HF animals. No signifi-
cant differences were observed in fecal triglyceride
excretion, although the combined data suggested an
increase. Excretion of intragastrically-administered [
14C]
cholesterol was also increased in HFPC-700 mice.
Unlike the results of the first experiment, excretion of
intragastrically-administered [
3H]sitostanol was not sig-
nificantly higher in HF mice supplemented with PC-700.
Thus calculated percentage cholesterol absorption was
lower in HFPL vs HF mice: 36.7 ± 2.0% vs 44.5 ± 2.4%
at 3 weeks (P = 0.03) and 37.9 ± 2.0% vs 52.1 ± 3.1% at
5 weeks (P =0 . 0 0 1 ) .T h ev a l i d i t yo ft h i sc a l c u l a t i o n
must be questioned however in view of the apparent
intestinal uptake of [
3H]sitostanol (as noted in the first
experiment). The combined data showed that PC-700
supplementation resulted in a significant increase in
fecal excretion of total lipid, unlabelled cholesterol and
radioactively-labelled intragastrically-administered cho-
lesterol (Table 4).
Liver lipid levels and intestinal uptake of cholesterol
Linear regression analysis was carried out in order to
determine whether there was any relationship between
liver lipid levels and the distribution of intragastrically-
administered [
14C]cholesterol between the liver and
feces of diet-fed animals. Results for PLRDME-supple-
mented mice are shown in Figure 1A, and those for PC-
700-supplemented mice are shown in Figure 1B. In both
cases, a strong positive correlation was found between
liver cholesterol and triglyceride levels and the hepatic
accumulation of intragastrically-administered [
14C]cho-
lesterol. At the same time, a negative correlation was
found between liver cholesterol and triglyceride levels
and fecal excretion of intragastrically-administered [
14C]
cholesterol.
Table 4 Effect of dietary milk phospholipids in the form of commercially-prepared PC-700 on liver and fecal lipid
parameters in mice given an intragastric gavage of radioactively-labelled cholesterol and sitostanol after 3 or 5 weeks
on high-fat diet
3 weeks 5 weeks Combined
HF HFPC-700 difference HF HFPC-700 difference HF HFPC-700 difference
(n = 10) (n = 9) (n = 9) (n = 10) (n = 19) (n = 19)
Liver
Total lipid (mg/
organ)
103 ± 10 80 ± 5 -22% 148 ± 18 82 ± 7 ** -45% 124 ± 11 81 ± 4 ** -35%
Cholesterol (μmol/
organ)
30 ± 3 17 ± 1 ** -45% 37 ± 4 16 ± 2 *** -57% 34 ± 3 16 ± 1 *** -51%
Triglyceride
(μmol/organ)
80 ± 13 52 ± 8 -35% 110 ± 14 41 ± 8 *** -63% 94 ± 10 46 ± 6 *** -51%
[
14C]cholesterol
(dpm/organ)
5377 ± 902 2150 ± 248 ** -60% 6390 ± 1006 2268 ± 305 *** -65% 5857 ± 664 2212 ± 194 *** -62%
[
3H]sitostanol
(dpm/organ)
403 ± 76 264 ± 31 -34% 310 ± 49 206 ± 28 -33% 359 ± 46 234 ± 21 * -35%
Feces
Total lipid
(mg/mouse/day)
15.5 ± 1.4 22.3 ± 1.7 ** +44% 12.3 ± 1.1 18.8 ± 2.0 * +53% 14.0 ± 1.0 20.4 ± 1.3 *** +46%
Cholesterol
(μmol/mouse/day)
6.8 ± 0.7 7.9 ± 0.6 +17% 6.8 ± 0.5 8.4 ± 0.5 * +24% 6.8 ± 0.4 8.2 ± 0.4 * +21%
Triglyceride
(μmol/mouse/day)
4.6 ± 1.1 6.1 ± 1.5 +33% 2.3 ± 0.6 3.7 ± 1.0 +62% 3.5 ± 0.7 4.9 ± 0.9 +38%
[
14C]cholesterol
(dpm/mouse/day)
10289 ± 675 12163 ± 437 * +18% 9075 ± 770 11208 ± 550 * +24% 9714 ± 515 11660 ± 364 ** +20%
[
3H]sitostanol
(dpm/mouse/day)
17778 ± 962 19490 ± 981 +10% 18173 ± 907 17552 ± 618 -3% 17965 ± 647 18470 ± 596 +3%
Results represent means ± SEM. Mice given the high-fat diet alone were designated HF. Mice given the high-fat diet supplemented with 2% by wt PC-700 were
designated HFPC-700. Data are provided for animals fed for 3 or 5 weeks. Combined data are shown on the right. Percentage difference between groups is
given in italics. Significant difference between HF and HFPC-700 by t-test: * P < 0.05, ** P < 0.01, *** P < 0.001.
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Page 6 of 12Further analysis of fecal lipids in mice supplemented with
PLRDME
Conversion of fecal cholesterol and triglyceride mea-
surements to mg units revealed that only one third of
total fecal lipid was accounted for by cholesterol and
triglyceride. Thin layer chromatography was therefore
carried out to determine what other lipids were present
and it was found that fecal samples contained appreci-
able amounts of fatty acid and in the case of PL-supple-
mented animals, high levels of PL and ceramides. In
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Figure 1 Relationship between liver lipids and intragastrically-administered [
14C]cholesterol in the liver and feces of mice fed the
high-fat diet alone or the high-fat diet supplemented with milk phospholipids: (A) PLRDME or (B) PC-700. Data points represent
individual animals after 3 or 5 weeks of diet feeding. Open circles represent high-fat-fed mice (HF); filled circles represent milk phospholipid-
supplemented animals (HFPL or HFPC-700). A correlation coefficient (r
2) is shown in each panel together with its level of statistical significance.
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Page 7 of 12order to measure these latter lipids by ESI-MS, fecal
samples without radioactivity were required and a third
experiment was carried out in which one group of mice
(n = 10) were fed the HF diet and a second group (n =
10) was fed the HF diet supplemented with PLRDME.
Mice were fed for 8 weeks and 24-h fecal samples were
collected at 2 (n = 3), 4 (n = 4) and 8 weeks (n = 4)
from each cage of animals (n = 5 mice per cage). After
8 weeks, liver wt was not significantly different in HF vs
HFPL (1.65 ± 0.06 vs 1.44 ± 0.08 g, respectively), how-
ever when expressed as a ratio to body wt., HFPL mice
had significantly smaller livers (4.32 ± 0.23 vs 5.15 ±
0.15 g/100 g, P < 0.05). Total lipid was also significantly
reduced in the liver of HFPL animals (12.3 ± 0.4 vs 15.1
± 1.4 g/100 g, P < 0.05), predominantly due to a reduc-
tion in hepatic triglyceride (116.9 ± 6.6 vs 162.2 ± 23.2
μmol/g, P < 0.05). Plasma cholesterol but not plasma
triglyceride was significantly lower in HFPL mice (4.7 ±
0.4 vs 6.1 ± 0.3, P < 0.05 and 0.71 ± 0.06 vs 0.56 ± 0.07
mmol/l, n.s). These results demonstrated that PLRDME
supplementation reduced both hepatic and serum lipid
levels in this group of animals. Fecal PL and ceramide
levels were analysed by ESI-MS and fecal excretion was
calculated in units of nmol of lipid per mouse per day
(Table 5). In HF mice the predominant PL species in
feces were PC, lysoPC and SM. In HFPL mice the pre-
dominant species were PC and SM. All PL species were
significantly higher in the feces of HFPL vs HF animals.
PC was increased 2.8-fold, PI was increased 6.2-fold and
SM was increased 5.6-fold. The major PC species (in
descending order of abundance) and their fecal excre-
tion rates (nmol/mouse/day) in HF and HFPL mice
respectively were: PC 32:1, 18.5 ± 1.6 vs 59.3 ± 5.0, P <
0.001; PC 34:1, 17.8 ± 2.2 vs 35.8 ± 3.6, P < 0.001; PC
32:0, 6.0 ± 0.7 vs 44.7 ± 4.2, P < 0.001; PC 34:0, 3.0 ±
0.3 vs 43.2 ± 4.0, P < 0.001. The major SM species (in
descending order of abundance) and their fecal excre-
tion rates (nmol/mouse/day) in HF and HFPL mice
were: SM 24:1, 30.7 ± 2.8 vs 138.9 ± 12.5, P <0 . 0 0 1 ;
SM 16:0, 14.9 ± 1.7 vs 54.5 ± 6.3, P < 0.001; SM 22:0,
3 . 8±0 . 4v s9 7 . 1±9 . 6 ,P < 0.001; SM 24:0, 1.9 ± 0.2 vs
54.2 ± 4.7, P < 0.001. All ceramide species were also sig-
nificantly higher in the feces of HFPL vs HF animals
(i.e., 4.2-fold, 9.3-fold and 10.2-fold for ceramide (Cer),
monohexosylceramide (MHC) and dihexosylceramide
(DHC), respectively). The major ceramide species (in
descending order) and their fecal excretion rates (nmol/
mouse/day) in HF and HFPL mice were: Cer 16:0, 11.1
± 1.0 vs 41.6 ± 3.4, P < 0.001; Cer 18:1, 7.4 ± 0.9 vs 31.5
±2 . 7 ,P < 0.001; Cer 18:0, 4.2 ± 0.4 vs 20.4 ± 1.7, P <
0.001; Cer 22:0, 2.4 ± 0.2 vs 26.3 ± 2.6, P <0 . 0 0 1 ;C e r
24:0, 1.9 ± 0.2 vs 23.2 ± 2.4, P < 0.001. The three most
abundant MHC and DHC species (in descending order)
and their fecal excretion rates (nmol/mouse/day) in HF
and HFPL mice respectively were: DHC 22:0, 8.1 ± 0.4
vs 89.4 ± 5.1, P < 0.001; DHC 24:0, 4.9 ± 0.2 vs 87.5 ±
4.9, P < 0.001; DHC 16:0, 4.1 ± 0.2 vs 49.7 ± 3.6, P <
0.001; MHC 22:0, 3.5 ± 0.3 vs 39.1 ± 3.2, P < 0.001;
MHC 24:0, 2.0 ± 0.1 vs 36.1 ± 3.0, P <0 . 0 0 1 ;M H C
16:0, 1.7 ± 0.1 vs 13.4 ± 1.3, P < 0.001. We confirmed
that fecal cholesterol excretion was increased in mice
supplemented with PLRDME (as in the first study) and
found that this was due to a difference in free choles-
terol excretion (HFPL vs HF: 3344 ± 329 vs 2486 ± 228
nmol/day/mouse, P < 0.05). Interestingly, fecal choles-
teryl ester (CE) excretion was significantly lower in
HFPL mice. The most abundant CE species and their
fecal excretion rates (nmol/mouse/day) in HF and HFPL
mice respectively were: CE 16:0, 32.2 ± 2.4 vs 26.3 ±
1.6, P = 0.05; CE 18:1, 19.9 ± 1.4 vs 17.8 ± 1.2, P = 0.26,
n.s; CE 16:1, 16.4 ± 2.0 vs 10.8 ± 1.1, P < 0.05; CE 18:2,
14.4 ± 1.6 vs 10.5 ± 1.7, P = 0.11, n.s. ESI-MS measure-
ments of fecal triglyceride and diglyceride species con-
firmed that these lipids were not significantly different
between groups.
Analysis of hepatic phospholipids in mice supplemented
with PLRDME
In view of the higher levels of PL in the diet and in the
feces of HFPL mice, we questioned whether this PL was
associated with altered levels of hepatic PL (i.e., conco-
mitant with the observed decreases in hepatic triglycer-
ide and cholesterol). PL was measured directly in
duplicate samples of whole diet, and intake of individual
PL species was calculated for mice in the 8-week study
(i.e., the third experiment) in terms of nmol of PL
Table 5 Phospholipid and ceramide levels in the feces of
mice fed the high-fat diet alone (HF) or the high-fat diet
supplemented with milk phospholipids (HFPL) in the
form of phospholipid-rich dairy milk extract (PLRDME)
HF HFPL difference
nmol/mouse/day
Phosphatidylcholine 71 ± 7 272 ± 22 *** +281%
Lysophosphatidylcholine 60 ± 7 92 ± 8 ** +52%
Phosphatidylethanolamine 7 ± 1 13 ± 1 ** +79%
Phosphatidylinositol 3.1 ± 0.4 22.5 ± 2.6 *** +617%
Phosphatidylserine 3.3 ± 0.3 4.8 ± 0.4 * +43%
Sphingomyelin 55 ± 5 362 ± 34 *** +560%
Ceramide 29 ± 2 150 ± 13 *** +424%
Monohexosylceramide 10 ± 1 100 ± 8 *** +934%
Dihexosylceramide 23 ± 1 258 ± 15 *** +1017%
Trihexosylceramide 0.8 ± 0.1 2.5 ± 0.2 *** +212%
Results represent means ± SEM for 11 fecal samples in each group.
Percentage difference between groups is given in italics. Significant difference
between HF and HFPL by Student’s t-test: * P < 0.05, ** P < 0.01,
*** P < 0.001.
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Page 8 of 12consumed per mouse per day. PL species were measured
in the liver of mice sacrificed after 8 weeks on diet. All
PL species (with the exception of lysophospholipid)
were increased about 40-fold in the HFPL diet. Liver PL
levels were not increased however and in fact tended to
be lower in HFPL vs HF mice. Liver PC (the major PL
species in the liver) was significantly less in HFPL vs HF
livers (-21%, P < 0.05). The most abundant hepatic PL
species (in descending order) and their levels (nmol/
liver) in HF and HFPL mice were: PC 34:1, 1623 ± 101
vs 1223 ± 125, -25%, P < 0.05; PC 32:1, 1280 ± 140 vs
1029 ± 72, -20%, P = 0.12, ns; PC 34:2, 902 ± 110 vs
677 ± 57, -25%, P = 0.08; PC 38:6, 694 ± 54 vs 537 ±
44, -23%, P < 0.05; PC 36:3, 551 ± 47 vs 395 ± 29, -28%,
P <0 . 0 5 .T h em o s ta b u n d a n td ietary PL species con-
sumed by the HF and HFPL mice, respectively, were (in
nmol/mouse/day): PC 32:1, 91 vs 3175; PC 34:1, 45 vs
2525; PC 36:2, 38 vs 1051; and PC 32:0, 24 vs 1025.
Ceramide intake was also higher in HFPL mice (Table
6), particularly MHC and DHC, however hepatic cera-
mide levels tended to be lower. Total liver Cer was
lower by 22% in HFPL mice (P = 0.07). The most abun-
dant Cer species in the liver (in descending order) and
their level in HF and HFPL mice were (in nmol/liver):
Cer 24:1, 24 ± 2 vs 15 ± 1, -36%, P < 0.01; Cer 22:0,
20 ± 2 vs 16 ± 1, -17%, P = 0.23; Cer 24:0, 12 ± 2 vs 11
± 1, -10%, P = 0.49; Cer 16:0, 10 ± 1 vs 9 ± 1, -13%, P =
0.27. The most abundant MHC species in the liver (in
descending order) and their level in HF and HFPL mice
were (in nmol/liver): MHC 22:0, 9.9 ± 1.0 vs 6.2 ± 0.6,
-37%, P < 0.01; MHC 24:0, 5.3 ± 0.3 vs 3.9 ± 0.2, -26%,
P < 0.01; MHC 24:1, 5.3 ± 0.7 vs 3.6 ± 0.3, -32%,
P < 0.05.
Discussion
The present data support our previous work showing
that the addition of 1.2% by wt milk PLs to the diet
reduces hepatic cholesterol and triglyceride levels in
mice fed a high-fat diet [2]. Reduced lipid levels in the
liver of PL-supplemented mice were associated with a
reduction in hepatic accumulation of intragastrically-
administered [
14C]cholesterol and an increase in fecal
cholesterol excretion. These results suggest that one of
the mechanisms whereby milk PL extracts beneficially
reduce elevated hepatic lipid levels in mice fed an obe-
sogenic and/or atherogenic diet is by reducing intestinal
cholesterol uptake.
A number of different mechanisms can be proposed to
explain how dietary milk PL interferes with intestinal
cholesterol uptake. Firstly, it has been shown that pan-
creatic PLA2 hydrolysis of luminal PL is an important
prerequisite for intestinal cholesterol absorption [10,11]
and that excess PL can inhibit PLA2-dependent choles-
terol uptake [12]. Secondly, PL has a strong effect on
cholesterol solubilization in intestinal micelles [8] and
excess luminal PL may affect solubilization, thus shifting
the partition coefficient of cholesterol away from the
enterocyte membrane. A third possibility is that
increased PL concentration in the gut lumen results in
increased size and altered physical characteristics of
lipid micelles, thereby affecting the interaction of choles-
terol with specific protein transporters responsible for
intestinal transport [13]. A final possibility is that excess
luminal PL is able to stimulate cholesterol excretion in
the proximal part of the small intestine - a pathway that
has been termed: “transintestinal cholesterol efflux” or
TICE [14]. Both bile salts and PLs have been shown in
Table 6 Phospholipid and ceramide levels in the food and liver of mice fed the high-fat diet alone (HF) or the high-fat
diet supplemented with milk phospholipids in the form of phospholipid-rich dairy milk extract (PLRDME)
Food Intake Liver
HF HFPL difference HF HFPL difference
nmol/mouse/day nmol/whole organ
Phosphatidylcholine 279 11382 +3980% 7568 ± 620 5947 ± 412 * -21%
Phosphatidylethanolamine 270 12963 +4701% 2022 ± 152 1814 ± 99 -10%
Phosphatidylinositol 72 3242 +4403% 1211 ± 95 1019 ± 68 -16%
Phosphatidylserine 136 5002 +3613% 141 ± 10 129 ± 6 -8%
Lysophosphatidylcholine 662 1048 +58% 274 ± 92 222 ± 28 -19%
Sphingomyelin 245 9670 +3847% 739 ± 71 622 ± 20 -16%
Ceramide 41 87 +112% 75 ± 7 58 ± 4 -22%
Monohexosylceramide 29 858 +857% 24 ± 2 16 ± 1 ** -33%
Dihexosylceramide 45 1295 +1294% 2.7 ± 0.2 2.4 ± 0.2 -11%
Trihexosylceramide 5 6 +20% nd nd nd
Food intake data represent averages of duplicate measurements. Liver lipid results represent means ± SEM for 8 mice in each group. Percentage difference
between groups is given in italics. Significant difference between HF and HFPL by Student’s t-test: * P < 0.05, ** P < 0.01, *** P < 0.001.
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Page 9 of 12intestinal perfusion studies in mice to stimulate TICE
[15]. Support for this mechanism was unexpectedly
obtained in our first experiment in which mice were
supplemented with PLRDME. Fecal excretion of [
3H]
sitostanol was increased in PLRDME-supplemented ani-
mals (Table 2). After 8 weeks on diet, gene expression
of ABCG5 and ABCG8 in the proximal intestine (pro-
teins mediating plant sterol excretion from the entero-
cyte into the gut lumen) was also found to be
significantly increased (data not shown). Similar results
were not however obtained in the second experiment
with PC-700 (Table 4), suggesting that increased TICE
was not sufficient to explain increased sterol excretion
in PL-supplemented animals.
Previous studies have provided evidence that dietary
PLs have the ability to reduce intestinal cholesterol
absorption [5]. We therefore set out to calculate percen-
tage cholesterol absorption in the present study using a
fecal dual-isotope method that has been validated and
used extensively in mice [9]. This indirect method for
calculating percentage cholesterol absorption relies on
the assumption that intragastrically-administered [
3H]
sitostanol is not absorbed. Unexpectedly, this was not
the case in the present experiments, as evidenced by the
presence of [
3H]sitostanol in the liver of diet-fed mice.
Calculated percentages of absorbed cholesterol in the
present study were therefore unreliable and they should
be interpreted with caution.
Two studies have investigated the acute effects of milk
SM administered intragastrically to rats [7,16], while a
third involved feeding milk SM to mice over 4 days [8].
In this latter study, a dose of 0.1% by wt SM added to
normal dietary chow was found to reduce cholesterol
absorption by 20%. The physiological and/or therapeutic
relevance of this effect was not however investigated. In
the present experiments, milk PL extracts were fed for 3
or 5 weeks to mice fed a diet that induces many of the
atherogenic features characteristic of the metabolic syn-
drome in humans [17]. PL supplementation resulted in
a 20% to 60% decrease in hepatic cholesterol and a 15%
to 30% increase in fecal cholesterol excretion (Tables 2
and 4). Milk PL extracts were added to the high-fat diet
at a level of 1.2% by wt PL and the level of SM in
PLRDME and PC-700 was 22% and 28% of total PL,
respectively. The HFPL and HFPC-700 diets thus con-
tained about 0.3% by wt milk SM. Comparing this level
to that used in the short-term study by Eckhardt et al.
(i.e., 0.1%) [8], it can be proposed that the amount of
SM in our milk extracts may have been sufficient to
account for the observed intestinal effects. Other PL
species may also have contributed however - a possibi-
lity supported by studies showing that lecithin or PC
from different sources can affect intestinal cholesterol
absorption [6,18,19].
It is generally believed that increased flux of choles-
terol from the intestine to the liver, due to increased
dietary cholesterol, results in increased production of
oxysterols in the liver and activation of the LXR-SREBP-
1c pathway [20,21]. Fatty acid synthesis is enhanced,
promoting the production of hepatic triglycerides and
the development of liver steatosis. Reduced intestinal
cholesterol uptake therefore tends to have the opposite
effect, and this is a likely explanation for the ability of
dietary milk PLs to lower hepatic triglyceride levels.
Support for this scenario comes from studies with the
cholesterol absorption inhibitor ezetimibe, which has
been shown to reduce hepatic LXR activity and reduce
hepatic steatosis [22]. In previous experiments, we have
found that PLRDME supplementation causes a signifi-
cant decrease in LXR-regulated genes as well as the
expression of enzymes affecting fatty acid synthesis (e.g.,
fatty acid synthase and acetyl-CoA carboxylase) [2].
Additional work involving the direct measurement of
hepatic TG synthesis is nevertheless required to sub-
stantiate the link between reduced cholesterol absorp-
tion and reduced hepatic TG levels in PL-supplemented
mice.
Supplementation of the HF diet with 2.5% by wt
PLRDME (i.e.,1.2% by wt PL) resulted in an approxi-
mately 40-fold increase in the amount of individual PLs
in the diet (Table 6). This resulted in a significant
increase in fecal excretion of all PL species, however the
magnitude of the increase was much less than in the diet,
e.g., fecal excretion increased only 2.8-, 5.6-, 0.8- and 6.2-
fold for PC, SM, PE and PI, respectively. Comparing the
food intake data in Table 6 (expressed as nmol per
mouse per day) with the fecal excretion data in Table 5
(expressed in the same units), it can be calculated that
2.4%, 3.7%, 0.1% and 0.2% of PC, SM, PE and PI in the
diet appeared in the feces, which indicates that the added
PL was very efficiently absorbed. Interestingly, increased
PL absorption was not associated with a significant
increase in plasma PL levels (data not shown) nor in
levels of hepatic PLs (Table 6). In fact, liver PL levels
tended to be lower and liver PC was significantly reduced
(i.e., by 21%) in PLRDME-supplemented mice. Liver cera-
mide levels also tended to be lower, despite increased
amounts of dietary and fecal ceramide. Yunoki et. al.
have recently shown that glucosylceramide from corn
(added to the diet at a level of 0.5% by wt) reduced fatty
liver in Zucker fatty rats [23]. Duivenvoorden et. al. have
documented the lipid-lowering activity of dietary sphin-
golipids (including yeast ceramide) in genetically-induced
hyperlipidemic mice [24]. Furthermore, Feng et. al. have
recently demonstrated that ceramide inhibits cholesterol
uptake to a greater extent than SM in cultured human
intestinal cells [25]. Milk sphingolipids, including milk
ceramides, may therefore have contributed to the lipid-
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potentially beneficial effect of dietary ceramides is in
stark contrast to the detrimental role of endogenous cera-
mide biosynthesis that has been proposed to be of central
importance in the etiology of obesity, insulin resistance
and the metabolic syndrome [26,27].
The current results suggest that milk PL extracts
might be of therapeutic benefit in individuals with fatty
liver disease or those with hyperlipidemia. The extent to
which dietary PLs can affect plasma and liver lipid levels
remains to be determined however. Human studies
[28-30] carried out in a small number of individuals
support the concept that luminal or dietary lecithin (i.e.,
PC) can reduce intestinal cholesterol absorption in man.
In one of these studies, human subjects were infused
intraduodenally with a relatively large amount of lecithin
(150 mg/kg/h), which not only blocked cholesterol
absorption but actually “extracted” cholesterol from the
intestinal mucosa, reflected by ‘negative’ absorption
values [28]. In a second study, 10 hypertriglyceridemic
patients were treated with lecithin (10 g/day), and after
2-3 weeks, cholesterol absorption was reduced from 42
± 2% to 36 ± 2% (P < 0.05) [30]. The ability of milk PL
extracts to mimic and/or potentiate this effect deserves
further investigation.
Conclusions
The present experiments demonstrate that milk PL
extracts have beneficial effects on liver and intestinal
cholesterol metabolism in mice fed an obesogenic and/
or atherogenic diet. More specifically, the present work
provides evidence that milk PL extracts have the poten-
tial to reduce intestinal cholesterol uptake. Whether or
not this is of therapeutic relevance in man remains to
be determined.
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